Updated DAPT ESC guidelines
February 06,2018 | News | BioFreedom
BioFreedom now listed as stent of choice in ESC DAPT guidelines, for 1 month-ultra short DAPT in patients with stable CAD in whom longer DAPT regimes poses safety concerns.
(European Heart Journal (2018)39, 213-254)
HIGH BLEEDING RISK PATIENTS
January 20,2010 | News | BioFreedom
BioFreedom is the only active stent with CE mark for
ultra-short 1 month DAPT, in High bleeding Risk (HBR)
patients, supported by clinical data from a double-blind
randomized controlled trial.
ELDERLY PATIENTS WITH HIGH BLEEDING RISK
February 26,2018 | News | BioFreedom
In the pre-specified elderly subgroup of LEADERS FREE,
when considering age over 75 as sole criteria,
BioFreedom demonstrated a 0.7% definite or probable
stent thrombosis rate at one year.